tiprankstipranks
Novartis AG (MX:NVSN)
NYSE:NVSN
Mexico Market
NVSN
Novartis
RESEARCH TOOLSreports

Novartis (NVSN) Stock Forecast & Price Target

― Followers
See the Price Targets and Ratings of:

NVSN Analyst Ratings

Hold
4Ratings
Hold
2 Buy
1 Hold
1 Sell
Based on 4 analysts giving stock ratings to
Novartis
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NVSN Stock 12 Month Forecast

Average Price Target

$2,775.36
Based on 4 Wall Street analysts offering 12 month price targets for Novartis in the last 3 months. The average price target is $2,775.36 with a high forecast of $3,128.80 and a low forecast of $2,416.13. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2159":"$2,159","2644":"$2,644","3129":"$3,129","2401.5":"$2,401.5","2886.5":"$2,886.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3128.8023648,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.13K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2775.3635791466672,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.78K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2416.13071504,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.42K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2159,2401.5,2644,2886.5,3129],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2725,2756.061720369231,2787.1234407384613,2818.1851611076922,2849.246881476923,2880.3086018461536,2911.3703222153845,2942.4320425846154,2973.4937629538463,3004.5554833230767,3035.6172036923076,3066.6789240615385,3097.740644430769,{"y":3128.8023648,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2725,2728.8741214728207,2732.7482429456413,2736.6223644184615,2740.496485891282,2744.370607364103,2748.2447288369235,2752.1188503097437,2755.9929717825644,2759.867093255385,2763.7412147282057,2767.615336201026,2771.4894576738466,{"y":2775.3635791466672,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2725,2701.240824233846,2677.481648467692,2653.722472701538,2629.9632969353847,2606.204121169231,2582.444945403077,2558.685769636923,2534.926593870769,2511.167418104615,2487.4082423384616,2463.6490665723077,2439.8898908061537,{"y":2416.13071504,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2160.772,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2163.508,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2163.508,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2211.466,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2304.734,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2345.926,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2451.845,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2566.592,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2800.007,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2771,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2598,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2606,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2725,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$3,129Average Price Target$2,775Lowest Price Target$2,416
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on MX:NVSN
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$2,433.51→$2,416.13
Sell
―
Reiterated
07/22/26
Novartis (NVS) Receives a Sell from Goldman Sachs
Bank of America Securities Analyst forecast on MX:NVSN
Sachin Jain
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
07/21/26
Analysts' Top Healthcare Picks: Novartis (NVS), 4D Molecular Therapeutics (FDMT)
TD Cowen Analyst forecast on MX:NVSN
Steve Scala
TD Cowen
TD Cowen
$2,573.96→$3,128.8
Hold
―
Reiterated
06/11/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Insulet (NASDAQ: PODD) and Novartis (NYSE: NVS)
Argus Research Analyst forecast on MX:NVSN
Jasper Hellweg
Argus Research
Argus Research
$2,781.16
Buy
―
Assigned
06/04/26
Argus Research Reaffirms Their Buy Rating on Novartis (NVS)
Morgan Stanley Analyst forecast on MX:NVSN
Thibault Boutherin
Morgan Stanley
Morgan Stanley
$2,485.66→$2,954.98
Buy
―
Reiterated
03/26/26
Morgan Stanley Sticks to Its Buy Rating for Novartis (NVS)
Bernstein Analyst forecast on MX:NVSN
Justin Smith
Bernstein
Bernstein
―
Hold
―
Initiated
03/19/26
Novartis (NVS) Receives a New Rating from Bernstein
Berenberg Bank Analyst forecast on MX:NVSN
Kerry Holford
Berenberg Bank
Berenberg Bank
$2,016.34→$2,450.9
Hold
―
Assigned
03/06/26
Novartis (NVS) Receives a Hold from Berenberg Bank
Barclays Analyst forecast on MX:NVSN
Emily Field
Barclays
Barclays
―
Hold
―
Upgraded
01/06/26
Novartis upgraded to Equal Weight from Underweight at BarclaysNovartis upgraded to Equal Weight from Underweight at Barclays
HSBC Analyst forecast on MX:NVSN
Rajesh Kumar
HSBC
HSBC
$1,842.52→$1,946.81
Sell
―
Reiterated
12/10/25
Novartis price target raised to $112 from $106 at HSBCNovartis price target raised to $112 from $106 at HSBC
J.P. Morgan Analyst forecast on MX:NVSN
Richard Vosser
J.P. Morgan
J.P. Morgan
―
Hold
―
Reiterated
11/20/25
J.P. Morgan Sticks to Its Hold Rating for Novartis (NVS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on MX:NVSN
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$2,433.51→$2,416.13
Sell
―
Reiterated
07/22/26
Novartis (NVS) Receives a Sell from Goldman Sachs
Bank of America Securities Analyst forecast on MX:NVSN
Sachin Jain
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
07/21/26
Analysts' Top Healthcare Picks: Novartis (NVS), 4D Molecular Therapeutics (FDMT)
TD Cowen Analyst forecast on MX:NVSN
Steve Scala
TD Cowen
TD Cowen
$2,573.96→$3,128.8
Hold
―
Reiterated
06/11/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Insulet (NASDAQ: PODD) and Novartis (NYSE: NVS)
Argus Research Analyst forecast on MX:NVSN
Jasper Hellweg
Argus Research
Argus Research
$2,781.16
Buy
―
Assigned
06/04/26
Argus Research Reaffirms Their Buy Rating on Novartis (NVS)
Morgan Stanley Analyst forecast on MX:NVSN
Thibault Boutherin
Morgan Stanley
Morgan Stanley
$2,485.66→$2,954.98
Buy
―
Reiterated
03/26/26
Morgan Stanley Sticks to Its Buy Rating for Novartis (NVS)
Bernstein Analyst forecast on MX:NVSN
Justin Smith
Bernstein
Bernstein
―
Hold
―
Initiated
03/19/26
Novartis (NVS) Receives a New Rating from Bernstein
Berenberg Bank Analyst forecast on MX:NVSN
Kerry Holford
Berenberg Bank
Berenberg Bank
$2,016.34→$2,450.9
Hold
―
Assigned
03/06/26
Novartis (NVS) Receives a Hold from Berenberg Bank
Barclays Analyst forecast on MX:NVSN
Emily Field
Barclays
Barclays
―
Hold
―
Upgraded
01/06/26
Novartis upgraded to Equal Weight from Underweight at BarclaysNovartis upgraded to Equal Weight from Underweight at Barclays
HSBC Analyst forecast on MX:NVSN
Rajesh Kumar
HSBC
HSBC
$1,842.52→$1,946.81
Sell
―
Reiterated
12/10/25
Novartis price target raised to $112 from $106 at HSBCNovartis price target raised to $112 from $106 at HSBC
J.P. Morgan Analyst forecast on MX:NVSN
Richard Vosser
J.P. Morgan
J.P. Morgan
―
Hold
―
Reiterated
11/20/25
J.P. Morgan Sticks to Its Hold Rating for Novartis (NVS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
GKOSGlaukos
ARDXArdelyx
STOKStoke Therapeutics
MIRMMirum Pharmaceuticals
CSTLCastle Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novartis

3 Months
Thibault BoutherinMorgan Stanley
Success Rate
2/2 ratings generated profit
100%
Average Return
+13.25%
Copying Thibault Boutherin's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +13.25% per trade.
1 Year
Thibault BoutherinMorgan Stanley
Success Rate
2/2 ratings generated profit
100%
Average Return
+9.45%
Copying Thibault Boutherin's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +9.45% per trade.
2 Years
Thibault BoutherinMorgan Stanley
Success Rate
2/2 ratings generated profit
100%
Average Return
+9.45%
Copying Thibault Boutherin's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +9.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NVSN Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
3
3
3
2
3
Hold
5
3
3
2
2
Sell
0
0
0
0
1
Strong Sell
0
0
0
0
0
total
8
6
6
4
6
In the current month, NVSN has received 3 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. NVSN average Analyst price target in the past 3 months is 2,775.36.
Each month's total comprises the sum of three months' worth of ratings.

NVSN Financial Forecast

NVSN Earnings Forecast

Next quarter’s earnings estimate for NVSN is $39.27 with a range of $36.12 to $43.77. The previous quarter’s EPS was $42.20. NVSN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year NVSN has Performed in-line its overall industry.
Next quarter’s earnings estimate for NVSN is $39.27 with a range of $36.12 to $43.77. The previous quarter’s EPS was $42.20. NVSN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year NVSN has Performed in-line its overall industry.

NVSN Sales Forecast

Next quarter’s sales forecast for NVSN is $255.09B with a range of $246.17B to $260.10B. The previous quarter’s sales results were $252.44B. NVSN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year NVSN has Performed in-line its overall industry.
Next quarter’s sales forecast for NVSN is $255.09B with a range of $246.17B to $260.10B. The previous quarter’s sales results were $252.44B. NVSN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year NVSN has Performed in-line its overall industry.

NVSN Stock Forecast FAQ

What is MX:NVSN’s average 12-month price target, according to analysts?
Based on analyst ratings, Novartis AG’s 12-month average price target is 2,775.36.
    What is MX:NVSN’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:NVSN, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Novartis AG a Buy, Sell or Hold?
        Novartis AG has a consensus rating of Hold, which is based on 2 buy ratings, 1 hold ratings and 1 sell ratings.
          What is Novartis AG’s share price target?
          The average share price target for Novartis AG is 2,775.36. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $3,128.80 ,and the lowest forecast is $2,416.13. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Novartis AG?
            Novartis AG’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Streets Analysts.
              How can I buy shares of Novartis AG?
              To buy shares of MX:NVSN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.